Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders

Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders

Background: Checkpoint blockade therapy, in the form of immune checkpoint inhibitors (ICIs), is increasingly being used to prolong survival in cancer patients, but its use is limited by the occurrence of immune-related adverse events (irAEs). These can be serious and occasionally fatal. However, the...

Full description

Bibliographic Details
Main Authors:	Mohsin Shah, Mazen N. Jizzini, Imad E. Majzoub, Aiham Qdaisat, Cielito C. Reyes-Gibby, Sai-Ching J. Yeung
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2019-07-01
Series:	Journal of Immunotherapy and Precision Oncology
Subjects:	cancer checkpoint inhibitors immune checkpoint blockade immune-related adverse events oncologic emergency preexisting autoimmune diseases
Online Access:	https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_11_19

Similar Items

Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
by: Xin Liu, et al.
Published: (2024-04-01)

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
by: Pankti Reid, et al.
Published: (2023-12-01)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
by: Hyungjoo Kim, et al.
Published: (2022-05-01)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
by: Rachel L. Y. Ho, et al.
Published: (2021-07-01)

Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
by: Hua Zhu, et al.
Published: (2022-07-01)

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy
by: Roberta Zappasodi, et al.
Published: (2022-12-01)

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
by: Yaru Tian, et al.
Published: (2019-06-01)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
by: Robert A. Szczepaniak Sloane, et al.
Published: (2021-10-01)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
by: Qi-jie Zhang, et al.
Published: (2021-04-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives
by: Guanglin Cui
Published: (2022-05-01)

Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead
by: Basak Aru, et al.
Published: (2022-01-01)

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
by: Isobel S. Okoye, et al.
Published: (2017-09-01)

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
by: Jingye Li, et al.
Published: (2021-08-01)

Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy
by: Wen-Chien Wang, et al.
Published: (2022-12-01)

Modern cancer therapy: cryoablation meets immune checkpoint blockade
by: Qi Liu, et al.
Published: (2024-02-01)

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
by: Wei Xie, et al.
Published: (2019-11-01)

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
by: Hong Wei, et al.
Published: (2019-09-01)

Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
by: Dietz H, et al.
Published: (2021-11-01)

Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
by: Alexander Chi, et al.
Published: (2021-06-01)

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
by: Hwa Kyung Byun, et al.
Published: (2021-05-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
by: Xueyan Wang, et al.
Published: (2022-10-01)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
by: Shangqin Sun, et al.
Published: (2021-04-01)

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
by: Jianheng Peng, et al.
Published: (2023-06-01)

Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies
by: Yiqin Ding, et al.
Published: (2023-12-01)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
by: Yufei Xu, et al.
Published: (2022-10-01)

Photothermal therapies to improve immune checkpoint blockade for cancer
by: Preethi B. Balakrishnan, et al.
Published: (2020-12-01)

Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021
by: Hui Luo, et al.
Published: (2024-03-01)

An unsuspected complication with immune checkpoint blockade: a case report
by: Lucia Carril-Ajuria, et al.
Published: (2018-09-01)

Utilization of hypoxia-derived gene signatures to predict clinical outcomes and immune checkpoint blockade therapy responses in prostate cancer
by: Minhua Chen, et al.
Published: (2022-08-01)

Acquired Resistance to Immune Checkpoint Blockade Therapies
by: Xianda Zhao, et al.
Published: (2020-05-01)

Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
by: Guang-Long Ma, et al.
Published: (2023-04-01)

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma
by: Steven H. Sun, et al.
Published: (2021-10-01)

Combining photothermal ablation-based vaccine with immune checkpoint blockade for synergistic osteosarcoma immunotherapy
by: Xingyu Zhao, et al.
Published: (2021-01-01)

Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop
by: Ariel E. Marciscano, et al.
Published: (2018-01-01)

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
by: David M. Miller, MD, PhD, et al.
Published: (2017-09-01)

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
by: Hongen Kang, et al.
Published: (2023-08-01)

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
by: Zhirui Zeng, et al.
Published: (2022-09-01)